Status:
NOT_YET_RECRUITING
GLP-1 RA on Liver OMICS in MASLD
Lead Sponsor:
Medical College of Wisconsin
Conditions:
NAFLD
Diabetes
Eligibility:
All Genders
18-80 years
Brief Summary
In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue. Lipid droplet a...
Detailed Description
The study involves patients with a diagnosis of MASLD by histology and have diabetes/obesity. The 'omics' ( lipidomics, proteomics, metabolites, and inflammatory profiles and transcriptomics) data of ...
Eligibility Criteria
Inclusion
- known diagnosis of MASLD by histology, also have diabetes/ obesity
- on treatment with GLP-1 RA at stable dose
Exclusion
- unable to have a liver biopsy, recent change in medication for diabetes or hyperlipidemia
- on immunosuppression, liver or kidney transplant
- pregnancy
Key Trial Info
Start Date :
January 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06982378
Start Date
January 1 2026
End Date
December 1 2028
Last Update
October 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Froedtert Hospital
Milwaukee, Wisconsin, United States, 53226